论文部分内容阅读
[目的]探讨尿激酶联合苯那普利治疗IgA肾病的临床疗效。[方法]140例IgA肾病患按随机数字表法分为对照组(70例)和观察组(70例),观察组患者应用尿激酶加苯那普利联合治疗,对照组单纯应用苯那普利。比较两组的治疗效果。[结果]6个疗程后,观察组的尿蛋白量和Scr水平与治疗前相比明显降低,Alb水平和Ccr显著升高(P﹤0.05,0.01),且改善水平显著优于对照组(P﹤0.05);观察组的总有效率为74.3%(52/70),明显高于对照组51.4%(36/70),差异有统计学意义(χ2=7.83,P﹤0.01)。[结论]尿激酶联合苯那普利治疗IgA肾病疗效确切,能显著改善肾功能,优于单纯使用苯那普利,值得临床进一步推广应用。
[Objective] To investigate the clinical efficacy of urokinase combined with benazepril in the treatment of IgA nephropathy. [Methods] One hundred and forty patients with IgA nephropathy were divided into control group (70 cases) and observation group (70 cases) by random number table. The patients in observation group were treated with combination of urokinase and benazepril. The control group was treated with benazepril Lee. Compare the treatment effect of two groups. [Results] After 6 courses of treatment, urinary protein level and Scr level in observation group were significantly lower than those before treatment, Alb level and Ccr were significantly increased (P <0.05, 0.01), and the improvement level was significantly better than the control group (P <0.05). The total effective rate in the observation group was 74.3% (52/70), which was significantly higher than that in the control group (51.4%, 36/70). The difference was statistically significant (χ2 = 7.83, P <0.01). [Conclusion] Combination of urokinase and benazepril in the treatment of IgA nephropathy is effective and can significantly improve renal function. It is better than simply using benazapril, which deserves further clinical application.